公开(公告)号：EP2124898B1

公开(公告)日：2013-08-14

申请号：EP08780367.2

申请日：2008-01-10

申请人： Board of Regents, The University of Texas System ,  The Dow Chemical Company

发明人： WILLIAMS, Robert, O., III ,  JOHNSTON, Keith, P. ,  SINWAT, Prapasri ,  MCCONVILLE, Jason, T. ,  TALBERT, Robert ,  PETERS, Jay ,  WATTS, Alan, B. ,  ROGERS, True, L.

IPC分类号： A61K9/14 ,  A61K9/16 ,  A61K9/00 ,  A61K9/19

CPC分类号： A61K31/436 ,  A61K9/0075 ,  A61K9/0078 ,  A61K9/1623 ,  A61K9/1694 ,  A61K9/19 ,  A61K9/5161 ,  A61K9/5192 ,  A61K38/13

摘要： The present invention includes compositions and methods for making and using a rapid dissolving, high potency, substantially amorphous nanostructured aggregate for pulmonary delivery of tacrolimus and a stabilizer matrix comprising, optionally, a polymeric or non-polymeric surfactant, a polymeric or non-polymeric saccharide or both, wherein the aggregate comprises a surface area greater than 5 m2/g as measured by BET analysis and exhibiting supersaturation for at least 0.5 hours when 11-15-times the aqueous crystalline solubility of tacrolimus is added to simulated lung fluid.

公开(公告)号：EP2124898A1

公开(公告)日：2009-12-02

申请号：EP08780367.2

申请日：2008-01-10

申请人： Board of Regents, The University of Texas System ,  The Dow Chemical Company

发明人： WILLIAMS, Robert, O., III ,  JOHNSTON, Keith, P. ,  SINWAT, Prapasri ,  MCCONVILLE, Jason, T. ,  TALBERT, Robert ,  PETERS, Jay ,  WATTS, Alan, B. ,  ROGERS, True, L.

IPC分类号： A61K9/14

CPC分类号： A61K31/436 ,  A61K9/0075 ,  A61K9/0078 ,  A61K9/1623 ,  A61K9/1694 ,  A61K9/19 ,  A61K9/5161 ,  A61K9/5192 ,  A61K38/13

摘要： The present invention includes compositions and methods for making and using a rapid dissolving, high potency, substantially amorphous nanostructured aggregate for pulmonary delivery of tacrolimus and a stabilizer matrix comprising, optionally, a polymeric or non-polymeric surfactant, a polymeric or non-polymeric saccharide or both, wherein the aggregate comprises a surface area greater than 5 m2/g as measured by BET analysis and exhibiting supersaturation for at least 0.5 hours when 11-15-times the aqueous crystalline solubility of tacrolimus is added to simulated lung fluid.

摘要翻译： 本发明包括用于制备和使用快速溶解，高效力，基本上无定形纳米结构化聚集体用于肺移植他克莫司的组合物和方法，以及包含任选的聚合物或非聚合物表面活性剂，聚合物或非聚合物糖的稳定剂基质 或两者，其中所述骨料包含通过BET分析测量的大于5m 2 / g的表面积，并且当将他克莫司的水溶液结晶溶解度加入到模拟肺液中时，表现出过饱和至少0.5小时。

公开(公告)号：EP3288541B1

公开(公告)日：2020-09-02

申请号：EP15766292.5

申请日：2015-09-02

申请人： Board of Regents, The University of Texas System

发明人： WILLIAMS, Robert ,  WATTS, Alan ,  PETERS, Jay ,  RAFFA CARVALHO, Simone

IPC分类号： A61K9/14 ,  A61K9/72 ,  A61K31/167 ,  A61K31/137 ,  A61K31/58 ,  A61P11/00

公开(公告)号：EP3288541A1

公开(公告)日：2018-03-07

申请号：EP15766292.5

申请日：2015-09-02

申请人： Board of Regents, The University of Texas System

发明人： WILLIAMS, Robert ,  WATTS, Alan ,  PETERS, Jay

IPC分类号： A61K9/14 ,  A61K9/72 ,  A61K31/167 ,  A61K31/137 ,  A61K31/58 ,  A61P11/00

摘要： Dual and triple therapy combinations of drugs formulated as brittle matrix particles with a high surface area are provided herein. These particle formulations may be used in inhalation or aerosol administration techniques to provide the drug combinations to the lungs. In some aspects, these compositions may be used to treat a respiratory disease or disorder such as asthma or COPD.